Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis

Autor:	Anna Mazzeo, Carol J. Whelan, Morie A. Gertz, John L. Berk, Violaine Planté-Bordeneuve, Isabel Conceição, Brian M. Drachman, Hartmut Schmidt, Peter D. Gorevic, Merrill D. Benson, Arnt V. Kristen, Josep Maria Campistol Plana, Michael Polydefkis, Teresa Coelho, Giampaolo Merlini, Josep Gamez, Annabel K. Wang, Peter J. Dyck, Thomas H. Brannagan, Peter Aquino, Arvind Narayana, Laura Obici, Kemi Olugemo
Rok vydání:	2021
Předmět:	Transthyretin medicine.medical_specialty Neurology biology business.industry Amyloidosis biology.protein Medicine Neurology (clinical) business medicine.disease Polyneuropathy Dermatology
Zdroj:	Journal of the Neurological Sciences. 429:117867
ISSN:	0022-510X
DOI:	10.1016/j.jns.2021.117867
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5529c1a92561aa88bfde97b2ca9fd9c8 https://doi.org/10.1016/j.jns.2021.117867 Zobrazit plný text záznamu Full Text from ScienceDirect